The purpose of the assessment is to evaluate multiple new pharmaceuticals for the treatment of Chronic Hepatitis C.
Final version of the assessment was published in December 2015
Below is the documentation provided by the Joint Assessment authoring team:
WP5-SA6 Final Appendix Feedback Complete 17122015
WP5-SA6 Final Appendix Content Complete Update January 2016
WP5-SA6 Final Version of Assessment Complete Update January 2016
New Pharmaceuticals for the treatment of chronic Hepatitis C_Rapid REA_Final_Dec 2015_1